

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

GAU1653
Box SEQ

Inventor(s): CHOO et al.

Appln. No.: 09

424,487

Series Code ↑

Series No. ↑

Filed: February 29, 2000

Hon. Commissioner of Patents

Washington, D.C. 20231

Group Art Unit 1653

Examiner: D. Srivastava

Atty. Dkt. *P 264975

M#

Client Ref

Appln. Title: NUCLEIC ACID BINDING PROTEINS

Sir:

REPLY/AMENDMENT LETTER

Date: June 11, 2001

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim A. <input checked="" type="checkbox"/> NOT made B. <input type="checkbox"/> Withdrawn C. <input type="checkbox"/> made herewith D. <input type="checkbox"/> made previously For B & C See <u>Required Separate Paper</u> (Pat-256)		Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims		44	**minus 44	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims		3	***minus 3	0	x \$80/\$40 =	+ \$0	102/202
4. If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time (leave blank if this is a reissue application)					add	+ \$270/\$135 =	+ \$0 104/204
5. Original due Date: May 9, 2001		<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo)	\$110/\$55 =			+ \$ 55	115/215
		(2 mos)	\$390/\$195 =				116/216
		(3 mos)	\$890/\$445 =				117/217
		(Usable <u>only</u> for ≤ 2mo.OA --- 4 mos)	\$1390/\$695 =				118/218
		(Usable <u>only</u> for 30 day/1mo.OA --- 5 mos)	\$1890/\$945 =				128/228
7. Enter any previous extension fee paid since above original due date and subtract					- \$0		
8. Extension Fee Attached					+ \$ 55		
9. If <u>Terminal Disclaimer</u> attached, add Rule 20(d) official fee					+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),					+ \$180	+ \$0	126
or if Rule 97(d) Request					+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)					+ \$710/355	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)					x \$710/355 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)					+ \$710/355	+ \$0	1179/1279
14. Petition fee for						+ \$0	
15. TOTAL FEE ENCLOSED =					\$ 55		

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 71278 264975

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Perry E. Van Over

Sig:

Reg. No. 42197

Fax: (202) 822-0944

Tel: (202) 861-3545

1100 New York Avenue, NW

Ninth Floor

Washington, DC 20005-3918

Tel: (202) 861-3000

Atty/Sec: PEV/MJG

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re PATENT APPLICATION of

CHOO et al.

Application No.: 09/424,487

Filed: February 29, 2000

Title: NUCLEIC ACID BINDING PROTEINS



Group Art Unit: 1653

Examiner: D. Srivastava

16
D
6/21/01
RECEIVED

JUN 13 2001

TECH CENTER 1600/2900

* * * * *

June 11, 2001
(June 9, 2001 = Saturday and
June 10, 2001 = Sunday)

**AMENDMENT
and
SUBMISSION PURSUANT TO 37 CFR 1.821-1.825**

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated April 9, 2001, and in order to comply with the requirements for patent applications containing nucleic acid sequence and/or amino acid sequence disclosures, please amend the above-referenced application as follows.

IN THE SPECIFICATION:

Page 5, please delete the last full paragraph, and replace it with the following new paragraph:

D
Figure 2 shows the amino acid sequence of three fingers (SEQ ID NOS: 12-14, respectively in order of appearance) used for phage display selection in the determination of recognition code.

06/12/2001 RHARIS1 00000123 09424487

01 FC:215

55.00 OP